Results from the highly anticipated LRP (Lipid-Rich Plaque) study will be presented during a late-breaking clinical trial session at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21–25 September, San Diego, USA).
The LRP Study a prospective, multicentre study is designed to identify a correlation between lipid core plaque and the occurrence of major adverse cardiovascular events (MACE) within two years. At the time of index procedure, intravascular ultrasound (IVUS) plus near infrared spectroscopy (NIRS) technology was used, which a press release reports that can now be found on the Makoto imaging system and Dualpro IVUS+NIRS catheter, to assess vessel structure and plaque composition.
The press release reports that recent studies have shown that LCP is an underlying cause of serious cardiac events. It adds that NIRS has demonstrated the capability to readily distinguish stable coronary plaque from potentially dangerous lipid core plaque compared with IVUS-alone.
The LRP study results will be presented in the late-breaking clinical trial session at the symposium that takes place on the Monday of the meeting (24 September) at 10.40am (San Diego Convention Center, Main Arena, Hall F, ground level).
Jason Bottiglieri, president and CEO of Infraredx, comments: ““The LRP Study was several years in the making and has the potential to change the field of interventional cardiology. We stand firm in our commitment to provide cardiologists with the most precise imaging tool required to predict and ultimately prevent heart attacks.”
Additionally on Monday, Infraredx will also sponsor a satellite programme—“The new frontier: can we finally predict and start treating vulnerable plaque?”. The discussion will be moderated by the principal Investigator of the LRP Study, Ron Waksman (MedStar Heart and Vascular Institute, Washington, DC, USA).